NoBACZ Healthcare Partners with GLA Pharma to bring Cuvestrequin™ to New Zealand

NoBACZ Healthcare Partners with GLA Pharma to bring Cuvestrequin™ to New Zealand: A Breakthrough Product supporting Equine Wound Care.

NoBACZ Healthcare is proud to continue its partnership with GLA Pharma, and together they are now launching Cuvestrequin™ in New Zealand.

Cuvestrequin is a pioneering new product supporting wound care in horses, developed specifically for equine veterinary professionals. Designed to meet the unique challenges of wound management in horses, Cuvestrequin delivers NoBACZ’s trusted physical and microbial barrier technology in a formula carefully curated for equine skin.

This unique product will be available to veterinary practices throughout New Zealand, distributed exclusively by GLA Pharma, a leading distributor of animal health products. The official launch took place at the New Zealand Veterinary Association conference in Auckland on the 23^rd June.

David Charles, International Business Development Manager at NoBACZ Healthcare, commented on the partnership:

“It brings us great pleasure to announce that we are continuing to partner with GLA Pharma to bring yet another of our products to the New Zealand market. GLA Pharma has great success bringing innovative, unique products to veterinarians and animal owners. Having launched our livestock products last year, we are thrilled to be working with them again to launch Cuvestrequin. The standard of equine care and veterinary medicine in New Zealand is internationally recognised, and by partnering with GLA Pharma, we can provide Cuvestrequin as another essential tool in equine vets’ toolkits.”

Peter Blaikie, Founder and MD at GLA Pharma at GLA Pharma announced that:

“We’re incredibly excited to be launching Cuvestrequin here in New Zealand as we’ve been trialling the product with key equine veterinarians throughout the country over the last few months. The feedback from our leading equine veterinarians has been extremely positive, particularly around its ability to reduce the reliance on bandaging while supporting faster wound healing.  To quote – ‘. It’s going to be a game changer in how wounds are managed now’.

Cuvestrequin is the third of NoBACZ Healthcare’s innovative products for which GLA Pharma has exclusive distribution rights in New Zealand. The other two NoBACZ Healthcare livestock products are UMBIREZ™ and Ambugreen™. Together, the three products offer veterinary professionals progressive and effective solutions, backed by NoBACZ’s commitment to science-led innovation.

Visit www.glapharma.co.nz to find out more.